论文部分内容阅读
目的探讨甲磺酸氨氯地平联合缬沙坦治疗老年高血压患者的临床疗效及安全性。方法选取清城区凤城社区卫生服务中心门诊2013年3月—2016年6月就诊治疗的90例老年高血压患者,随机分为A组、B组、C组,每组30例。A组给予甲磺酸氨氯地平联合缬沙坦治疗,B组给予单用甲磺酸氨氯地平治疗,C组给予缬沙坦治疗,治疗时间均为3个月。治疗结束后,比较并分析三组患者的临床疗效、心率及血压情况及不良反应发生情况及实验室指标的变化等。结果三组患者经相应方案治疗后A组的总有效率(96.67%)均明显高于B组(80.00%)、C组(66.67%),差异有统计学意义(P<0.05);三组血压及心率均较本组治疗前降低,差异有统计学意义(P<0.05);治疗前,三组患者血压及心率比较差异无统计学意义(P>0.05);治疗后,A组血压及心率均明显低于B组、C组(P<0.05)。三组不良事件发生率比较,差异无统计学意义(P>0.05)。三种治疗方案对肝肾功能及血液无明显不良反应,安全可靠。结论甲磺酸氨氯地平联合缬沙坦治疗老年高血压疾病,有较好的临床疗效,且安全可靠,对血液及肝肾功能无明显毒副作用。
Objective To investigate the clinical efficacy and safety of amlodipine mesylate combined with valsartan in the treatment of elderly patients with hypertension. Methods 90 elder patients with hypertension who were treated in Fengcheng Community Health Service Center of Qingcheng District from March 2013 to June 2016 were randomly divided into A group, B group and C group, with 30 cases in each group. Group A was given amlodipine mesylate combined with valsartan, group B was treated with amlodipine mesylate alone, and group C was given valsartan. The treatment time was 3 months. After treatment, the clinical efficacy, heart rate and blood pressure, adverse reactions and changes of laboratory indexes in three groups were compared and analyzed. Results The total effective rate (96.67%) in group A was significantly higher than that in group B (80.00%) and group C (66.67%) after treatment with the corresponding regimen, the difference was statistically significant (P <0.05) Blood pressure and heart rate were lower than before treatment in this group, the difference was statistically significant (P <0.05); before treatment, the three groups of patients with no significant difference in blood pressure and heart rate (P> 0.05); after treatment, Heart rate were significantly lower than the B group, C group (P <0.05). There was no significant difference between the three groups in the incidence of adverse events (P> 0.05). Three kinds of treatment of liver and kidney function and blood no significant adverse reactions, safe and reliable. Conclusion Amlodipine mesylate combined with valsartan in the treatment of elderly patients with hypertension has good clinical efficacy, is safe and reliable, and has no obvious side effects on blood and liver and kidney functions.